AstraZeneca and Luye Pharma Group enter agreement for rights to Seroquel and Seroquel XR in the UK, China and other international markets
- Details
- Category: AstraZeneca
AstraZeneca has entered into an agreement with Luye Pharma Group, Ltd. (Luye Pharma) for the sale and licence of the rights to Seroquel and Seroquel XR in the UK, China and other international markets, including Brazil, Australia, Saudi Arabia, Mexico, South Korea, Thailand, Argentina, Malaysia and South Africa.
Novo Nordisk participates in new research project Hypo-RESOLVE to investigate hypoglycaemia and its impact in diabetes
- Details
- Category: Novo Nordisk
Within the newly started European research project Hypo-RESOLVE, 23 leading international players from academia, industry and civil society have joined forces to find better solutions to alleviate the burden and consequences of hypoglycaemia in diabetes. Diabetes is a global epidemic, currently affecting around 60 million people in Europe. Hypoglycaemia is a common and serious complication of diabetes, particularly affecting people with diabetes on insulin therapy; very low levels of blood glucose can lead to cognitive decline, cardiovascular events and even death.
Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma
- Details
- Category: Novartis
Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma after two or more lines of systemic therapy including diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma and DLBCL arising from follicular lymphoma.
Roche reports a strong start in 2018
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced that in the first three months of 2018, Group sales rose 6% to CHF 13.6 billion. Sales in the Pharmaceuticals Division increased 7% to CHF 10.7 billion. A key growth driver was Ocrevus, used to treat two forms of multiple sclerosis. It continued its strong growth in the US and was launched in Europe and additional countries worldwide during the first quarter.
Boehringer Ingelheim R&D pushes to transcend disease boundaries
- Details
- Category: Boehringer Ingelheim
Family-owned pharmaceutical company Boehringer Ingelheim has presented its latest pipeline updates at a Research & Development press conference entitled 'Transcending Disease Boundaries', at its global headquarters in Ingelheim, Germany. The company's R&D strategy and current pipeline has the potential to deliver 15 new medicines for approval by 2025 (probability adjusted).
Novartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
- Details
- Category: Novartis
Novartis announced the launch of its FocalView app, an ophthalmic digital research platform created with ResearchKit. FocalView aims to allow researchers to track disease progression by collecting real-time, self-reported data directly from consenting patients. By adapting the design of clinical trials to suit the daily routine of patients, the app may reduce barriers to participation, leading to a more nuanced understanding of ophthalmic diseases and potentially accelerating the development of novel treatments.
New OCREVUS (ocrelizumab) data at AAN demonstrate significant reductions in disease activity and disability progression in relapsing multiple sclerosis
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new OCREVUS (ocrelizumab) data were presented at the 70th American Academy of Neurology (AAN) Annual Meeting from 21-27 April in Los Angeles, California. The data showcase the efficacy of OCREVUS in relapsing multiple sclerosis (RMS) through several measures of underlying disease activity and disability progression, including magnetic resonance imaging (MRI), cognitive function, and spinal fluid biomarkers of inflammation and neurodegeneration.
More Pharma News ...
- Pfizer doses first patient using investigational mini-dystrophin gene therapy for the treatment of Duchenne muscular dystrophy
- Red Cross and Novo Nordisk announce ground-breaking partnership to tackle chronic care in humanitarian crises
- FDA grants Breakthrough Therapy Designation for Roche's Hemlibra in haemophilia A without inhibitors
- Novartis renews commitment to malaria elimination, investing USD 100 million to research and develop next-generation antimalarials
- Boehringer Ingelheim and Lilly announce an academic collaboration with University of Oxford
- Bristol-Myers Squibb announces worldwide collaboration with Janssen to develop and commercialize next-generation cardiovascular therapy
- GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics